Abstract
The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Keywords: Anti-IgE, omalizumab, severe asthma.
Current Drug Targets
Title:Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Volume: 16 Issue: 2
Author(s): Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Rosa Terracciano and Rosario Maselli
Affiliation:
Keywords: Anti-IgE, omalizumab, severe asthma.
Abstract: The humanized monoclonal anti-IgE antibody omalizumab is currently the only biologic drug approved for asthma treatment. Omalizumab inhibits allergic responses by binding to serum immunoglobulins E (IgE), thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of down-regulating the expression of high affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both peripheral blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Moreover, some recent studies suggest potential benefits of omalizumab also in non allergic phenotypes of severe asthma. Very interesting are also further recent reports referring to the potential inhibitory effect of omalizumab with regard to bronchial structural changes, especially occurring in severe asthma and globally defined as airway remodeling. Omalizumab is relatively well tolerated, and only very rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent asthma, inadequately controlled by high doses of standard inhaled treatments.
Export Options
About this article
Cite this article as:
Pelaia Girolamo, Vatrella Alessandro, Teresa Busceti Maria, Gallelli Luca, Terracciano Rosa and Maselli Rosario, Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666141219122157
DOI https://dx.doi.org/10.2174/1389450116666141219122157 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of T Lymphocytes in the Development of Rheumatoid Arthritis. Implications for Treatment
Current Pharmaceutical Design Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Role of Galectins in Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Provocation Tests in Diagnosing Drug Hypersensitivity
Current Pharmaceutical Design Enzyme Inhibitors
Current Bioactive Compounds Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer
Current Drug Targets The Role of Mast Cells in the Structural Alterations of the Airways as a Potential Mechanism in the Pathogenesis of Severe Asthma
Current Pharmaceutical Design Development of New H1 Antihistamines: The Importance of Pharmacokinetics in the Evaluation of Safe and Therapeutically Effective Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Prospects of Developing Medicinal Therapeutic Strategies and Pharmaceutical Design for Effective Gluten Intolerance Treatment
Current Pharmaceutical Design TRP Channels and Pain
Current Pharmaceutical Design Cytokine Antibody Arrays: A Promising Tool to Identify Molecular Targets for Drug Discovery
Combinatorial Chemistry & High Throughput Screening High Cytotoxicity and Apoptotic Effects of Natural Bioactive Benzofuran Derivative on the MCF-7 Breast Cancer Cell Line
Combinatorial Chemistry & High Throughput Screening Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Thirty Years of Dutch Drugs and Driving Research: Strengths and Limitations of the On-The-Road Highway Driving Test and Future Challenges
Current Psychopharmacology Diagnostics and Therapy of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitides
Current Pharmaceutical Design Subject Index To Volume 2
Current Immunology Reviews (Discontinued) Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery Statistical Analysis, Optimization, and Prioritization of Virtual Screening Parameters for Zinc Enzymes Including the Anthrax Toxin Lethal Factor
Current Topics in Medicinal Chemistry